ライフサイエンスコーパス: uterine cancer

1 ose with esophageal, gastric, pancreatic, or uterine cancer.

2 ted at short-term follow-up for treatment of uterine cancer.

3 ncreased mortality risk in women with occult uterine cancer.

4 and most aggressive form of ovarian or extra-uterine cancer.

5 ey, liver, ovarian, pancreatic, melanoma, or uterine cancer.

6 al cancer subtypes, including PTEN-deficient uterine cancer.

7 vanced age was the strongest risk factor for uterine cancer.

8 t and progression of the most common type of uterine cancer.

9 omy for recurrence after surgical staging of uterine cancer.

10 formation for decision making for women with uterine cancer.

11 imaging to determine the anatomic origin of uterine cancer.

12 ogy and Obstetrics (FIGO) staging system for uterine cancer.

13 rotomy for comprehensive surgical staging of uterine cancer.

14 y the association between clomiphene use and uterine cancer.

15 equently inactivated in brain, prostate, and uterine cancer.

16 e involved in metastasis in both ovarian and uterine cancer.

17 s in prostate cancer, testicular cancer, and uterine cancer.

18 ing locoregional recurrence in patients with uterine cancer.

19 the initiation and metastasis of high-grade uterine cancer.

20 panic White (hereafter, White) patients with uterine cancer.

21 ching nor talc was associated with breast or uterine cancer.

22 NBS on three cancers: ovarian, bladder, and uterine cancer.

23 activating mutations in tamoxifen-associated uterine cancer.

24 te care product use and breast, ovarian, and uterine cancers.

25 and bladder, lung, pancreatic, prostate, and uterine cancers.

26 om most cancers, but are notably enriched in uterine cancers.

27 may be a useful marker for aggressive human uterine cancers.

28 eatly disproportionate amount of deaths from uterine cancers.

29 ms1, increases the chances of colorectal and uterine cancers.

30 st HRs for liver (3.31), pancreas (2.19) and uterine cancer (1.78).

31 endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases

32 The risk of uterine cancer (42%) exceeded that for colorectal cancer

33 7878 due to pancreatic cancer; 209314 due to uterine cancer; 421628 due to kidney cancer; 487518 due

34 While RNRi are not routinely used for uterine cancers, a retrospective analysis of patients tr

35 and Relevance: Although the overall risk for uterine cancer after RRSO was not increased, the risk fo

36 ur exclusively within high-grade subtypes of uterine cancer and can drive tumorigenesis and metastasi

37 Objective: To determine the risk for uterine cancer and distribution of specific histologic s

38 have less cardiovascular disease, breast and uterine cancer and menopausal symptoms than those eating

39 The occurrence of uterine cancer and precancerous uterine lesions was dete

40 seful for determining the anatomic origin of uterine cancer and provides helpful information regardin

41 Using an autochthonous mouse model of uterine cancer and the administration of respiratory hyp

42 More than 90% of patients with uterine cancers and 83% with ovarian cancer will not die

43 ts, unemployed women, women with ovarian and uterine cancers and choriocarcinoma, higher disease stag

44 ess radiotherapy for breast, colorectal, and uterine cancers and fewer chemotherapy sessions.

45 ly nor in randomized trials for treatment of uterine cancers, and the associated toxic effects and pa

46 trogen-related toxicities such as breast and uterine cancer are mediated through ERalpha.

47 n; and the incidence of breast, ovarian, and uterine cancer are not available.

48 requently develops benign fibroid tumors but uterine cancers are relatively rare.

49 aneously arising estrogen-associated de novo uterine cancer, are significantly less frequent in tamox

50 with temporal and extratemporal features and uterine cancer as a prominent oncologic association.

51 leeding caused by endometrial hyperplasia or uterine cancer as a result of prolonged exposure to tumo

52 ovarian cancer mortality (OR = 1.5), and 3) uterine cancer as a risk factor for pancreatic cancer mo

53 The AUC for detection of uterine cancer based on endometrial thickness in mm was

54 tic, melanoma, kidney, bladder, gastric, and uterine cancer being treated in the first line were incl

55 ith a confirmed histopathologic diagnosis of uterine cancer between April 1, 2000, and March 31, 2009

56 ung cancer, endocrine therapy with increased uterine cancer (but reduced contralateral breast cancer)

57 as been identified as a potent suppressor of uterine cancer, but the biological modes of action of LK

58 s including kidney, breast, lung, liver, and uterine cancers, but not in prostate cancer.

59 and contributes to the pathogenesis of human uterine cancer by activating COX-2 expression.

60 Race and ethnicity of patients with uterine cancer, categorized as Asian, Black, Hispanic, a

61 in MCF-7 breast adenocarcinoma and Ishikawa uterine cancer cell lines.

62 g either HMGA1a or COX-2 in high-grade human uterine cancer cells blocks anchorage-independent cell g

63 inds directly to the COX-2 promoter in human uterine cancer cells in vivo and activates its expressio

64 Significance: Elevated IGFBP2 secretion by uterine cancer cells with heterozygous PPP2R1A mutations

65 nvasion and migration ability of ovarian and uterine cancer cells.

66 mong Hispanic men and women and pancreas and uterine cancer deaths among Hispanic women increased fro

67 tage at diagnosis with racial disparities in uterine cancer deaths at the population-based level are

68 71.5%] White individuals), there were 16 797 uterine cancer deaths between 2010 and 2017, correspondi

69 spective cohort study included patients with uterine cancer diagnosed from 2000 to 2019, from 17 Surv

70 Censoring occurred at uterine cancer diagnosis, hysterectomy, last follow-up,

71 Among 208 587 women diagnosed with uterine cancer during 2000-2017 (15 983 [7.7%] were Asia

72 ely affect prognosis of patients with occult uterine cancer, empirical evidence has been limited and

73 d White patients who received a diagnosis of uterine cancer from January 1, 2004, to December 31, 201

74 of the involved ovary and that a concomitant uterine cancer has been excluded.

75 Breast cancers, bladder cancers, and uterine cancers have spatial patterns that are particula

76 he Black population, with the highest HR for uterine cancer (HR, 1.87; 95% CI, 1.63-2.15), and for 7

77 ons may explain in part the reduced rates of uterine cancer in Asian countries compared with those in

78 erms of detecting the presence or absence of uterine cancers in women with abnormal uterine bleeding.

79 Uterine cancer incidence has been increasing, particular

80 Laparoscopic surgical staging for uterine cancer is feasible and safe in terms of short-te

81 ted that laparoscopic surgical management of uterine cancer is superior for short-term safety and len

82 Uterine cancer is the most common cancer of the female g

83 ortance: The link between BRCA mutations and uterine cancer is unclear.

84 tion between tamoxifen therapy and secondary uterine cancers is uncommon but well established; howeve

85 estrogen and progesterone receptors, but in uterine cancers, it is likely no longer under control of

86 Among 162 500 patients with uterine cancer (median [IQR] age at diagnosis, 61 [54-69

87 association of subtype-specific trends with uterine cancer mortality and with the role of tumor subt

88 both men and women in all US census regions, uterine cancer mortality increased in all regions for wo

89 Critically important to reducing uterine cancer mortality is the development of more effe

90 5RHH-siAXL treatment reduces metastasis in a uterine cancer mouse xenograft model, without causing an

91 BMI was associated with an increased risk of uterine cancer (OR 1.10, 95% CI 1.05-1.15; p < 0.001) an

92 to 65,499 single nuclei from samples of five uterine cancer patients and validate the clustering usin

93 hows promise in the treatment of ovarian and uterine cancer patients.

94 efits of minimally invasive hysterectomy for uterine cancer, population-level data describing the pro

95 depression, hepatitis C, hyperlipidemia, and uterine cancer post-hysterectomy.

96 In this cohort study of patients with uterine cancer, racial and ethnic disparities in surviva

97 ved kappa s of 0.36 and 0.25 for ovarian and uterine cancers, respectively, exceeded chance expectati

98 results suggest that clomiphene may increase uterine cancer risk (rate ratio (RR) = 1.79, 95% confide

99 (BC); however, its chronic use can increase uterine cancer risk and induce tamoxifen resistance.

100 sitive associations between BMI and lung and uterine cancer risk as well as the inverse association b

101 Uterine cancer risk increased with clomiphene dose (RR =

102 Clomiphene may increase uterine cancer risk, with higher doses leading to higher

103 may be of concern with regard to breast and uterine cancer risk.

104 Risks were increased for uterine cancer (RR = 1.55; 95% CI, 1.03 to 2.32) and non

105 cation of PhyloFrame to breast, thyroid, and uterine cancers shows marked improvements in predictive

106 To detect uterine cancer, simpler and more specific index tests ar

107 The fall in uterine cancers slowed down (-4%) to 4.7/100 000.

108 sted associations of race and ethnicity with uterine cancer-specific survival (primary outcome) in th

109 Location-stratified analyses found worse uterine cancer-specific survival among Black patients co

110 In total, 61 patients with uterine cancer stages I through III after surgery entere

111 Racial and ethnic disparities in uterine cancer survival are well-documented; however, li

112 use and esophageal, gastric, pancreatic, or uterine cancer survival were not observed.

113 equently inactivated in brain, prostate, and uterine cancers that acts as a phosphatase on phosphatid

114 echanism is specific to tamoxifen-associated uterine cancer, the concept of treatment-induced signali

115 Despite the high prevalence of uterine cancers, the molecular events that lead to neopl

116 ing that longer wait times from diagnosis of uterine cancer to definitive surgery have a negative imp

117 The prevalence of uterine cancer, uterine neoplasms of uncertain malignant

118 ciated with incontinence and falls; cervical/uterine cancer was associated with falls and osteoporosi

119 Uterine cancer was identified in 73 (1 in 528) women who

120 Using a mouse model of PTEN-deficient uterine cancer, we describe a surprising inhibitory role

121 Through 1999, 39 uterine cancers were ascertained by questionnaire or can

122 dian age 45.6 (IQR: 40.9 - 52.5), 8 incident uterine cancers were observed (4.3 expected; observed to

123 stric, 878 [2.7%] pancreatic, and 716 [2.2%] uterine cancers) were reported.

124 acial survival disparity among patients with uterine cancer, while insurance status represented the m

125 database to identify women with stage I-III uterine cancer who underwent hysterectomy from 2006 to 2

126 g cancer diagnosis by 2030, and melanoma and uterine cancer will become the fifth and sixth most comm

127 uates the overall survival for patients with uterine cancer with distant organ metastasis treated wit

128 rcoma, two clinically aggressive subtypes of uterine cancer with few therapeutic options.

129 There were 36 cases of uterine cancer with tamoxifen and 23 with raloxifene (RR

130 ultimately developed bulky endometrioid-type uterine cancers with 100% mortality by 8 months of age.

131 s likely to have thromboembolic sequelae and uterine cancer), women without a uterus, and women at hi